Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director Leslie Norwalk sold 1,250 shares of the business's stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $168.06, for a total transaction of $210,075.00. Following the completion of the transaction, the director owned 2,838 shares in the company, valued at $476,954.28. The trade was a 30.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Neurocrine Biosciences Price Performance
Shares of NASDAQ NBIX opened at $163.12 on Tuesday. Neurocrine Biosciences, Inc. has a 1 year low of $122.14 and a 1 year high of $169.57. The company's 50-day moving average is $143.35 and its 200 day moving average is $139.85. The stock has a market capitalization of $16.40 billion, a P/E ratio of 25.13, a P/E/G ratio of 1.23 and a beta of 0.39.
Institutional Investors Weigh In On Neurocrine Biosciences
Hedge funds and other institutional investors have recently bought and sold shares of the business. Nilsine Partners LLC purchased a new stake in Neurocrine Biosciences in the fourth quarter worth approximately $1,197,000. Ruffer LLP purchased a new stake in Neurocrine Biosciences in the fourth quarter worth approximately $2,479,000. Korea Investment CORP boosted its holdings in Neurocrine Biosciences by 94.3% in the third quarter. Korea Investment CORP now owns 71,689 shares of the company's stock worth $10,064,000 after purchasing an additional 34,800 shares during the last quarter. Envestnet Asset Management Inc. boosted its holdings in Neurocrine Biosciences by 2.4% in the third quarter. Envestnet Asset Management Inc. now owns 202,846 shares of the company's stock worth $28,476,000 after purchasing an additional 4,807 shares during the last quarter. Finally, CIBC Private Wealth Group LLC boosted its holdings in Neurocrine Biosciences by 17,250.0% in the third quarter. CIBC Private Wealth Group LLC now owns 7,981 shares of the company's stock worth $1,120,000 after purchasing an additional 7,935 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company's stock.
Analyst Ratings Changes
Several equities analysts recently issued reports on NBIX shares. Wolfe Research started coverage on shares of Neurocrine Biosciences in a research report on Tuesday, February 24th. They set an "outperform" rating and a $160.00 price target on the stock. Zacks Research upgraded shares of Neurocrine Biosciences from a "strong sell" rating to a "hold" rating in a research report on Wednesday, April 15th. Wall Street Zen upgraded shares of Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a research report on Saturday, April 25th. The Goldman Sachs Group started coverage on shares of Neurocrine Biosciences in a research report on Tuesday, June 2nd. They set a "buy" rating and a $213.00 price target on the stock. Finally, HC Wainwright boosted their price target on shares of Neurocrine Biosciences from $192.00 to $215.00 and gave the company a "buy" rating in a research report on Tuesday, April 7th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, Neurocrine Biosciences has an average rating of "Moderate Buy" and an average price target of $187.52.
View Our Latest Research Report on Neurocrine Biosciences
Neurocrine Biosciences Company Profile
(
Get Free Report)
Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine's operations encompass drug discovery, clinical development and commercialization activities.
The company's lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
